Much like Johnson & Johnson's
But, Johnson & Johnson and Abbott can afford to wait for discretionary spending on boob jobs and LASIK to rebound in the years ahead. In the mean time, Abbott also obtains Advance Medical Optics' cataract surgery and contact lens care products, which should be more recession-proof. Even after taking on Advanced Medical Optics' $1.5 billion in debt, Abbott still thinks the acquisition will be neutral to this year's earnings and start contributing to earnings next year.
With Advanced Medical Optics out of the way, the big question is who's next? It seems to me that the cosmetic laser companies are ripe for the picking. Syneron Medical
Buying shares with the hope of the company getting acquired is rarely a good move, but investors that can follow the same long-term thinking that Abbott and J&J do should be rewarded as they buy at these bargain-basement prices. Eventually.
Syneron Medical is a pick of the Motley Fool Hidden Gems Pay Dirt and Rule Breakers newsletters. Whether you like your companies big or small, dividend-laden or with multibagger written all over them, we've got a newsletter for you.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter. The Fool has a disclosure policy.
More from The Motley Fool
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Analysts think these three diabetes stocks could soar more than 50% this year. But are they right?
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.